Novartis' top drugs based on revenue 2018

Multiple sclerosis drug Gilenya was Novartis’ best-selling pharmaceutical during 2018, with a total revenue of 3.34 billion U.S. dollars worldwide. For several years, cancer drug Gleevec (glivec) was the company’s blockbuster drug, until it went generic in 2016 facing a significant sales decrease. However, Novartis is one of the big pharma companies with the lowest share of its top 3 products related to total sales. This broadly-based revenue makes it less vulnerable to revenue losses through patent expirations.

A view on the company

Novartis is based in Basel, Switzerland, and is the world’s second largest pharmaceutical company based on prescription drug sales. Interestingly, another leading drug manufacturer – Roche – is based also in Basel, making it the only city to be home to two global top 10 pharma companies. Both companies are deeply involved in the research, development, and manufacturing of cancer treatments. Novartis generates nearly 40 percent of its pharmaceutical revenue from oncologic products, and Roche around 60 percent.

Development of segments and divisions

Through its subsidiary Alcon, Novartis was also the second largest company worldwide in the field of ophthalmology products. However, in April 2019, Alcon’s spin-off from Novartis was completed, making it a wholly independent company. With Sandoz, Novartis has also a strong generic drug division. Sandoz makes around 10 billion U.S. dollars of revenue annually. Until 2014-2015, Novartis also had three other divisions which have since been sold: consumer health products, vaccines and diagnostics, and animal health. Thus, the company’s development shows a clear focus on human medicine and pharmaceuticals.
Welcome to Statista!

We are the global leading platform for business data from 600 industries and 50 countries.

Our 700 employees believe that facts cause big changes and promote brilliant ideas. We want to offer you the best basis for fast and effective decisions: Learn more.
Novartis AG's top 10 drugs based on revenue in 2018
(in million U.S. dollars)
Revenue in million U.S. dollars
Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $49 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$588 / Year

Statista Accounts: Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
Related Studies: Available to Download in PDF or PPTX Format
Top pharmaceutical drugs
Top pharmaceutical drugs

All Information
in one Presentation

Top pharmaceutical drugs

Everything On "Top pharmaceutical drugs" in One Document: Edited and Divided into Handy Chapters. Including Detailed References.

Other Reports & Dossiers
Statista is a great source of knowledge, and pretty helpful to manage the daily work.
Christof Baron

Christof Baron
CEO, MindShare Germany

Statistics on "Novartis"
  • Global positioning
  • Company overview
  • Revenue distribution
The most important statistics
  • Research and development
  • Miscellaneous
Discover Statista
Need help with using Statista for your research? Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.

Statista Accounts: Access All Statistics. Starting from $588 / Year
Learn more about how Statista can support your business.